INCY - Incyte Corp Stock Price, Fair Value and News

52.67USD-0.05 (-0.09%)Delayed as of 18 Apr 2024, 03:24 pm ET

Market Summary

USD52.67-0.05

Delayedas of 18 Apr 2024, 03:24 pm

-0.09%

INCY Stock Price

View Fullscreen

INCY RSI Chart

INCY Valuation

Market Cap

11.8B

Price/Earnings (Trailing)

19.8

Price/Sales (Trailing)

3.2

EV/EBITDA

9.38

Price/Free Cashflow

23.84

INCY Price/Sales (Trailing)

INCY Profitability

Operating Margin

93.10%

EBT Margin

22.57%

Return on Equity

11.51%

Return on Assets

8.81%

Free Cashflow Yield

4.2%

INCY Fundamentals

INCY Revenue

Revenue (TTM)

3.7B

Rev. Growth (Yr)

9.35%

Rev. Growth (Qtr)

10.26%

INCY Earnings

Earnings (TTM)

597.6M

Earnings Growth (Yr)

606.51%

Earnings Growth (Qtr)

17.41%

Breaking Down INCY Revenue

52 Week Range

52.2875.74

(Low)(High)

Last 7 days

-4.2%

Last 30 days

-8.1%

Last 90 days

-13.8%

Trailing 12 Months

-28.6%

How does INCY drawdown profile look like?

INCY Financial Health

Current Ratio

3.75

Debt/Equity

Debt/Cashflow

27.46

INCY Investor Care

Shares Dilution (1Y)

0.70%

Diluted EPS (TTM)

2.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.5B	3.5B	3.6B	3.7B
2022	3.1B	3.3B	3.3B	3.4B
2021	2.7B	2.7B	2.9B	3.0B
2020	2.2B	2.4B	2.5B	2.7B
2019	2.0B	2.0B	2.1B	2.2B
2018	1.5B	1.7B	1.8B	1.9B
2017	1.2B	1.3B	1.4B	1.5B
2016	857.9M	941.2M	1.0B	1.1B
2015	581.0M	644.4M	633.8M	753.8M
2014	373.7M	371.6M	484.6M	511.5M
2013	332.0M	347.1M	371.7M	354.9M
2012	98.7M	168.4M	212.1M	297.1M
2011	184.6M	151.5M	151.4M	94.5M
2010	49.4M	89.6M	129.7M	169.9M
2009	0	0	0	9.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Incyte Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	baker bros. advisors lp	acquired	-	-	1,086	-
Mar 28, 2024	clancy paul j	acquired	22,958	56.97	403	-
Mar 28, 2024	harrigan edmund	acquired	23,528	56.97	413	-
Mar 25, 2024	trotta matteo	acquired	-	-	7,828	evp, gm, dermatology us
Feb 14, 2024	hoppenot herve	acquired	-	-	41,577	chairman / ceo
Feb 14, 2024	stamoulis christiana	acquired	-	-	7,377	evp & chief financial officer
Feb 14, 2024	swain paula j	acquired	-	-	7,377	evp, human resources
Feb 14, 2024	flannelly barry p	acquired	-	-	7,377	evp & general manager us
Feb 14, 2024	stein steven h	acquired	-	-	7,377	evp & chief medical officer
Feb 14, 2024	iyengar vijay k	acquired	-	-	7,377	evp, gmapps

Which funds bought or sold INCY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	180 WEALTH ADVISORS, LLC	added	4.47	-27,047	271,405	0.05%
Apr 16, 2024	Berger Financial Group, Inc	sold off	-100	-3,796,790	-	-%
Apr 15, 2024	NorthCrest Asset Manangement, LLC	reduced	-8.33	-76,115	376,287	0.01%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-36.65	-785,172	1,061,290	0.03%
Apr 15, 2024	Wealth Alliance Advisory Group, LLC	unchanged	-	-25,725	251,807	0.06%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	added	13.03	14,085	566,488	-%
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	added	14.93	899	21,934	-%
Apr 15, 2024	Sunbelt Securities, Inc.	reduced	-9.35	-11,924	55,261	0.01%
Apr 15, 2024	Davis Investment Partners, LLC	reduced	-7.05	-198,202	655,215	0.29%
Apr 15, 2024	CX Institutional	sold off	-100	-211,540	-	-%

Are Funds Buying or Selling INCY?

Are funds buying INCY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INCY

No. of Funds

Unveiling Incyte Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	dodge & cox	7.2%	16,090,421	SC 13G/A
Feb 13, 2024	vanguard group inc	10.05%	22,519,381	SC 13G/A
Jan 24, 2024	blackrock inc.	10.8%	24,297,249	SC 13G/A
Dec 08, 2023	vanguard group inc	10.02%	22,466,463	SC 13G/A
Jun 08, 2023	blackrock inc.	10.5%	23,468,952	SC 13G/A
Mar 15, 2023	baker bros. advisors lp	16.3%	36,280,967	SC 13D/A
Feb 14, 2023	dodge & cox	8.7%	19,362,935	SC 13G/A
Feb 09, 2023	vanguard group inc	9.68%	21,533,818	SC 13G/A
Jan 25, 2023	blackrock inc.	8.9%	19,836,617	SC 13G/A
Mar 10, 2022	baker bros. advisors lp	16.4%	36,269,307	SC 13D/A

Recent SEC filings of Incyte Corp

View All Filings

Date Filed	Form Type	Document
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 27, 2024	3	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 25, 2024	SC 13G	Major Ownership Report
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading

Peers (Alternatives to Incyte Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Incyte Corp News

Latest updates

Incyte Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	10.3%	1,013	919	955	809	927	823	911	733	863	813	706	605	790	621	688	569	579	552	530	498	528
Cost Of Revenue	16.1%	70.00	60.00	68.00	57.00	59.00	55.00	51.00	43.00	44.00	40.00	38.00	29.00	36.00	34.00	33.00	27.00	32.00	30.00	29.00	23.00	26.00
Costs and Expenses	17.3%	826	704	761	784	857	685	657	617	752	578	565	506	625	615	457	1,233	484	417	431	424	446
S&GA Expenses	9.7%	294	268	284	316	273	266	253	210	226	191	169	154	167	121	118	111	136	103	106	124	108
R&D Expenses	18.3%	444	376	401	407	501	384	347	353	-	335	344	307	406	438	287	1,085	313	281	289	271	-891
EBITDA Margin	23.8%	0.25*	0.20*	0.18*	0.17*	0.18*	0.19*	0.21*	0.20*	0.21*	0.23*	0.17*	0.22*	-	-	-	-	-	-	-	-	-
Interest Expenses	29.1%	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Income Taxes	11.7%	70.00	63.00	74.00	30.00	52.00	36.00	68.00	33.00	-443	28.00	22.00	16.00	18.00	12.00	17.00	17.00	15.00	20.00	3.00	2.00	2.00
Earnings Before Taxes	15.9%	271	234	278	52.00	81.00	149	229	71.00	120	209	172	69.00	168	-3.51	307	-704	126	148	109	104	71.00
EBT Margin	26.5%	0.23*	0.18*	0.16*	0.15*	0.16*	0.17*	0.19*	0.18*	0.19*	0.21*	0.15*	0.20*	-	-	-	-	-	-	-	-	-
Net Income	17.4%	201	171	204	22.00	28.00	113	161	38.00	564	182	149	54.00	150	-15.20	290	-720	111	128	105	102	69.00
Net Income Margin	37.3%	0.16*	0.12*	0.10*	0.09*	0.10*	0.26*	0.28*	0.30*	0.32*	0.18*	0.12*	0.18*	-	-	-	-	-	-	-	-	-
Free Cashflow	-0.1%	148	148	307	-105	284	296	174	216	115	255	173	206	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	6.2%	6,782	6,388	6,208	5,798	5,841	5,510	5,319	5,054	4,933	4,199	3,905	3,661	3,561	3,307	3,212	2,752	3,427	3,215	2,948	2,754	2,646
Current Assets	5.5%	4,645	4,403	4,264	3,972	4,093	3,821	3,626	3,288	3,119	2,924	2,620	2,450	2,360	2,159	2,078	1,716	2,481	167	2,059	1,905	1,832
Cash Equivalents	-0.4%	3,213	3,227	3,131	2,821	2,951	2,692	2,437	2,258	2,059	2,001	1,799	1,672	1,515	1,500	1,329	1,046	1,834	1,703	1,417	1,301	1,165
Inventory	10.1%	63.00	57.00	36.00	41.00	42.00	46.00	55.00	35.00	28.00	21.00	17.00	17.00	16.00	17.00	16.00	14.00	11.00	7.00	7.00	7.00	7.00
Net PPE	2.5%	752	733	749	742	739	716	721	729	724	687	661	595	560	498	454	410	378	347	339	338	320
Goodwill	0%	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156	156
Liabilities	9.3%	1,592	1,457	1,468	1,335	1,471	1,284	1,234	1,191	1,163	1,050	969	934	950	917	868	815	828	792	700	669	720
Current Liabilities	10.3%	1,240	1,125	1,119	1,006	1,157	1,007	927	886	854	743	660	624	631	606	557	503	513	133	367	365	425
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	18.00	18.00	17.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	19.00	19.00	18.00	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.00	18.00	18.00	17.00
Shareholder's Equity	5.2%	5,190	4,931	4,741	4,463	4,370	4,227	4,085	3,863	3,770	3,149	2,936	2,728	2,611	2,391	2,345	1,938	2,598	2,423	2,247	2,086	1,926
Retained Earnings	494.1%	160	-40.69	-211	-415	-437	-465	-578	-739	-777	-1,341	-1,523	-1,672	-1,726	-1,876	-1,861	-2,151	-1,430	-1,541	-1,670	-1,775	-1,877
Additional Paid-In Capital	1.4%	5,016	4,949	4,926	4,857	4,792	4,721	4,689	4,626	4,567	4,509	4,477	4,421	4,353	4,277	4,218	4,102	4,044	3,973	3,926	3,870	3,814
Shares Outstanding	0.1%	224	224	223	223	223	222	221	221	220	220	220	220	-	-	-	-	-	-	-	-	-
Float	-	-	-	11,700	-	-	-	14,200	-	-	-	16,000	-	-	-	19,100	-	-	-	15,400	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-0.1%	147,729	147,835	306,526	-105,603	283,662	296,381	174,157	215,741	115,351	255,098	172,944	206,095	107,321	182,115	269,382	-683,417	131,618	270,415	152,960	155,663	83,838
Share Based Compensation	25.0%	59,990	48,000	54,520	53,379	52,679	45,404	46,496	43,841	48,222	42,694	44,732	47,358	45,261	43,800	46,303	42,513	42,023	43,359	40,615	40,592	37,323
Cashflow From Investing	-798.8%	-154,500	-17,189	-7,429	-28,559	-20,912	-28,402	-12,480	-16,748	-66,047	-32,754	-49,145	-59,753	-102,730	-14,453	-43,258	-108,560	-30,028	12,284	-45,147	-24,563	-36,097
Cashflow From Financing	100.9%	346	-37,256	12,868	4,009	-2,480	-14,311	15,901	96.00	9,005	-19,343	3,679	12,835	11,872	931	56,407	2,499	29,320	2,894	9,010	4,487	4,063

INCY Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 3,695,649	$ 3,394,635	$ 2,986,267
Costs and expenses:
Cost of product revenues (including definite-lived intangible amortization)	254,990	206,997	150,991
Research and development	1,627,594	1,585,936	1,458,179
Selling, general and administrative	1,161,293	1,002,140	739,560
Loss on change in fair value of acquisition-related contingent consideration	29,202	12,149	14,741
(Profit) and loss sharing under collaboration agreements	2,045	7,973	37,019
Total costs and expenses	3,075,124	2,815,195	2,400,490
Income from operations	620,525	579,440	585,777
Interest income and other, net	172,348	39,932	10,647
Interest expense	(2,551)	(2,666)	(1,908)
Unrealized gain (loss) on long term investments	43,893	(87,590)	(24,072)
Income before provision (benefit) for income taxes	834,215	529,116	570,444
Provision (benefit) for income taxes	236,616	188,456	(378,137)
Net income	$ 597,599	$ 340,660	$ 948,581
Net income per share:
Basic (in dollars per share)	$ 2.67	$ 1.53	$ 4.30
Diluted (in dollars per share)	$ 2.65	$ 1.52	$ 4.27
Shares used in computing net income per share:
Basic (in shares)	223,628	222,004	220,428
Diluted (in shares)	225,928	223,958	222,074
Product revenues, net
Revenues:
Total revenues	$ 3,165,168	$ 2,746,897	$ 2,322,012
Product royalty revenues
Revenues:
Total revenues	523,481	482,738	569,255
Milestone and contract revenues
Revenues:
Total revenues	$ 7,000	$ 165,000	$ 95,000

INCY Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,213,376	$ 2,951,422
Marketable securities—available-for-sale (amortized cost $442,816 and $292,580 as of December 31, 2023 and 2022 respectively; allowance for credit losses $0 as of December 31, 2023 and 2022)	442,667	287,543
Accounts receivable	743,557	644,879
Inventory	62,972	41,995
Prepaid expenses and other current assets	182,830	167,011
Total current assets	4,645,402	4,092,850
Restricted cash	1,845	1,698
Long term investments	187,716	133,676
Inventory	206,965	78,964
Property and equipment, net	751,513	739,310
Finance lease right-of-use assets, net	25,535	26,298
Other intangible assets, net	123,545	129,219
Goodwill	155,593	155,593
Deferred income tax asset	631,886	457,941
Other assets, net	52,107	25,435
Total assets	6,782,107	5,840,984
Current liabilities:
Accounts payable	109,601	277,546
Accrued compensation	153,348	138,761
Accrued and other current liabilities	935,569	701,053
Finance lease liabilities	3,439	3,179
Acquisition-related contingent consideration	38,422	36,538
Total current liabilities	1,240,379	1,157,077
Acquisition-related contingent consideration	173,578	184,462
Finance lease liabilities	29,162	30,083
Other liabilities	149,151	99,243
Total liabilities	1,592,270	1,470,865
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 400,000,000 shares authorized; 224,286,862 and 222,746,719 shares issued and outstanding as of December 31, 2023 and 2022, respectively	224	223
Additional paid-in capital	5,016,122	4,792,041
Accumulated other comprehensive income	13,106	15,069
Retained earnings (accumulated deficit)	160,385	(437,214)
Total stockholders’ equity	5,189,837	4,370,119
Total liabilities and stockholders’ equity	$ 6,782,107	$ 5,840,984

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

CEO	Mr. Herve Hoppenot
WEBSITE	incyte.com
INDUSTRY	Biotechnology
EMPLOYEES	2324

Incyte Corp Frequently Asked Questions

What is the ticker symbol for Incyte Corp? What does INCY stand for in stocks?

INCY is the stock ticker symbol of Incyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Incyte Corp (INCY)?

As of Wed Apr 17 2024, market cap of Incyte Corp is 11.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers.

What is the fair value of INCY stock?

You can check INCY's fair value in chart for subscribers. The fair value of Incyte Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Incyte Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INCY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Incyte Corp a good stock to buy?

The fair value guage provides a quick view whether INCY is over valued or under valued. Whether Incyte Corp is cheap or expensive depends on the assumptions which impact Incyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INCY.

What is Incyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, INCY's PE ratio (Price to Earnings) is 19.8 and Price to Sales (PS) ratio is 3.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INCY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Incyte Corp's stock?

In the past 10 years, Incyte Corp has provided 0.017 (multiply by 100 for percentage) rate of return.